Back to discover

Protein / target

Beta-arrestin-1

Encoded byARRB1P49407Homo sapiensSwiss-Prot
Small-molecule tractable
Druggability
Structure with Ligand
2
Research papers

Protein at a glance

Biological role

Insulin-like growth factor receptor binding

Strongest disease association

Cardiomyopathy, Hypertrophic

Via encoding gene ARRB1 · Genetic evidence · score 0.34

Research activity

Emerging research

2 papers · latest 2023

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Functions in regulating agonist-mediated G protein-coupled receptor (GPCR) signaling by mediating both receptor desensitization and resensitization processes.

View complete UniProt function annotation

Functions in regulating agonist-mediated G protein-coupled receptor (GPCR) signaling by mediating both receptor desensitization and resensitization processes (PubMed:37209686, PubMed:38175886, PubMed:40384633). During homologous desensitization, beta-arrestins bind to the GPCR-phosphorylated receptor and sterically preclude its coupling to the cognate G protein; the binding appears to require additional receptor determinants exposed only in the active receptor conformation. The beta-arrestins target many receptors for internalization by acting as endocytic adapters (CLASPs, clathrin-associated sorting proteins) and recruiting the GPRCs to the adapter protein 2 complex 2 (AP-2) in clathrin-coated pits (CCPs). However, the extent of beta-arrestin involvement appears to vary significantly depending on the receptor, agonist and cell type. Internalized arrestin-receptor complexes traffic to intracellular endosomes, where they remain uncoupled from G proteins. Two different modes of arrestin-mediated internalization occur. Class A receptors, like ADRB2, OPRM1, ENDRA, D1AR and ADRA1B dissociate from beta-arrestin at or near the plasma membrane and undergo rapid recycling. Class B receptors, like AVPR2, AGTR1, NTSR1, TRHR and TACR1 internalize as a complex with arrestin and traffic with it to endosomal vesicles, presumably as desensitized receptors, for extended periods of time. Receptor resensitization then requires that receptor-bound arrestin is removed so that the receptor can be dephosphorylated and returned to the plasma membrane. Involved in internalization of P2RY4 and UTP-stimulated internalization of P2RY2. Involved in phosphorylation-dependent internalization of OPRD1 ands subsequent recycling. Involved in the degradation of cAMP by recruiting cAMP phosphodiesterases to ligand-activated receptors. Beta-arrestins function as multivalent adapter proteins that can switch the GPCR from a G protein signaling mode that transmits short-lived signals from the plasma membrane via small molecule second messengers and ion channels to a beta-arrestin signaling mode that transmits a distinct set of signals that are initiated as the receptor internalizes and transits the intracellular compartment. Acts as a signaling scaffold for MAPK pathways such as MAPK1/3 (ERK1/2). ERK1/2 activated by the beta-arrestin scaffold is largely excluded from the nucleus and confined to cytoplasmic locations such as endocytic vesicles, also called beta-arrestin signalosomes. Recruits c-Src/SRC to ADRB2 resulting in ERK activation. GPCRs for which the beta-arrestin-mediated signaling relies on both ARRB1 and ARRB2 (codependent regulation) include ADRB2, F2RL1 and PTH1R. For some GPCRs the beta-arrestin-mediated signaling relies on either ARRB1 or ARRB2 and is inhibited by the other respective beta-arrestin form (reciprocal regulation). Inhibits ERK1/2 signaling in AGTR1- and AVPR2-mediated activation (reciprocal regulation). Is required for SP-stimulated endocytosis of NK1R and recruits c-Src/SRC to internalized NK1R resulting in ERK1/2 activation, which is required for the antiapoptotic effects of SP. Is involved in proteinase-activated F2RL1-mediated ERK activity. Acts as a signaling scaffold for the AKT1 pathway. Is involved in alpha-thrombin-stimulated AKT1 signaling. Is involved in IGF1-stimulated AKT1 signaling leading to increased protection from apoptosis. Involved in activation of the p38 MAPK signaling pathway and in actin bundle formation. Involved in F2RL1-mediated cytoskeletal rearrangement and chemotaxis. Involved in AGTR1-mediated stress fiber formation by acting together with GNAQ to activate RHOA. Appears to function as signaling scaffold involved in regulation of MIP-1-beta-stimulated CCR5-dependent chemotaxis. Involved in attenuation of NF-kappa-B-dependent transcription in response to GPCR or cytokine stimulation by interacting with and stabilizing CHUK. May serve as nuclear messenger for GPCRs. Involved in OPRD1-stimulated transcriptional regulation by translocating to CDKN1B and FOS promoter regions and recruiting EP300 resulting in acetylation of histone H4. Involved in regulation of LEF1 transcriptional activity via interaction with DVL1 and/or DVL2 Also involved in regulation of receptors other than GPCRs. Involved in Toll-like receptor and IL-1 receptor signaling through the interaction with TRAF6 which prevents TRAF6 autoubiquitination and oligomerization required for activation of NF-kappa-B and JUN. Binds phosphoinositides. Binds inositolhexakisphosphate (InsP6) (By similarity). Involved in IL8-mediated granule release in neutrophils. Required for atypical chemokine receptor ACKR2-induced RAC1-LIMK1-PAK1-dependent phosphorylation of cofilin (CFL1) and for the up-regulation of ACKR2 from endosomal compartment to cell membrane, increasing its efficiency in chemokine uptake and degradation. Involved in the internalization of the atypical chemokine receptor ACKR3. Involved in smoothened (SMO) localization to primary cilium (By similarity). Negatively regulates the NOTCH signaling pathway by mediating the ubiquitination and degradation of NOTCH1 by ITCH (PubMed:23886940). Participates in the recruitment of the ubiquitin-protein ligase to the receptor (PubMed:23886940). Involved in some MRGPRE-mediated signaling required to improve glucose tolerance: promotes phosphorylation of ALDOA downstream of MRGPRE activation, increasing glycolysis and leading to GLP-1 secretion (PubMed:40446798)

Subcellular location

CytoplasmNucleusCell membraneMembrane, clathrin-coated pitCell projection, pseudopodiumCytoplasmic vesicle
Domains and Gene Ontology detail (45)

Gene Ontology

  • Cchromatin
  • Cclathrin-coated pit
  • Ccytoplasm
  • Ccytoplasmic vesicle
  • Ccytoplasmic vesicle membrane
  • Ccytosol
  • Cendocytic vesicle membrane
  • CGolgi membrane
  • Clysosomal membrane
  • Cnucleoplasm
  • Cnucleus
  • Cplasma membrane

418 aa · 47 kDa · 2 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell migrationUniProtG protein-coupled signallingUniProt · GOTranscriptional regulationUniProt · GOImmune signallingUniProt · GO
View supporting evidence

Cell migration

  • ·Functions in regulating agonist-mediated G protein-coupled receptor (GPCR) signaling by…

G protein-coupled signalling

  • ·Functions in regulating agonist-mediated G protein-coupled receptor (GPCR) signaling by…
  • ·G protein-coupled receptor binding
  • ·desensitization of G protein-coupled receptor signaling pathway
  • ·G protein-coupled receptor internalization

Transcriptional regulation

  • ·Functions in regulating agonist-mediated G protein-coupled receptor (GPCR) signaling by…
  • ·transcription coactivator activity
  • ·DNA-templated transcription
  • ·positive regulation of transcription by RNA polymerase II

Immune signalling

  • ·Functions in regulating agonist-mediated G protein-coupled receptor (GPCR) signaling by…
  • ·negative regulation of interleukin-6 production
  • ·negative regulation of interleukin-8 production

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene ARRB1

Gene-level evidence surfaced through the gene ARRB1that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Cardiomyopathy, Hypertrophic
0.66Moderately supported

Genetic evidence dominant · Open Targets 0.56

Neoplasms
0.46Preliminary

Pathway evidence dominant · Open Targets 0.61 · no direct causal or clinical evidence

Noonan syndrome
0.35Preliminary

Pathway evidence dominant · Open Targets 0.53 · no direct causal or clinical evidence

Costello syndrome
0.33Preliminary

Pathway evidence dominant · Open Targets 0.50 · no direct causal or clinical evidence

Brugada syndrome
0.29Preliminary

Animal model evidence dominant · Open Targets 0.09 · no direct causal or clinical evidence

View evidence synthesis (5)
Cardiomyopathy, HypertrophicModerately supported
0.66
agreement 0.550.77
Genetic38%Pathway37%Animal model25%

Open Targets aggregate 0.56 · 3 independent evidence families

NeoplasmsPreliminary
0.46
agreement 0.290.64
Pathway76%Literature24%

Open Targets aggregate 0.61 · 2 independent evidence families · no direct causal or clinical evidence

Noonan syndromePreliminary
0.35
agreement 0.120.57
Pathway100%

Open Targets aggregate 0.53 · 1 independent evidence family · no direct causal or clinical evidence

Costello syndromePreliminary
0.33
agreement 0.100.56
Pathway100%

Open Targets aggregate 0.50 · 1 independent evidence family · no direct causal or clinical evidence

Brugada syndromePreliminary
0.29
agreement 0.060.52
Animal model100%

Open Targets aggregate 0.09 · 1 independent evidence family · no direct causal or clinical evidence

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Neoplasms0.61
Cardiomyopathy, Hypertrophic0.56
Noonan syndrome0.53
Costello syndrome0.50
Cardiofaciocutaneous syndrome0.37
Mouth Diseases0.14
Glioblastoma0.09
Brugada syndrome0.09

Tractability

Small moleculesEmerging

Feasibility evidence (structure with ligand) — no clinical-stage drug of this modality recorded.

AntibodiesEmerging

Feasibility evidence (go cc high conf and uniprot loc med conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (uniprot ubiquitination and database ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (7)
SM · Structure with LigandAB · GO CC high confAB · UniProt loc med confPR · UniProt UbiquitinationPR · Database UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Research activity

2 papers · to 2023

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Europe PMC papers linked directly to this protein.